Efficacy and Safety of a Somatostatin Analogue in Active Acromegaly
Acromegaly has been associated, in the past, with chronic discomfort leading from invalidism to death. Partial or complete removal of the pituitary gland has been the preferred mode of therapy but if the growth hormone (GH) secreting tumor cannot be totally removed GH oversecretion will persist.
KeywordsGrowth Hormone Carpal Tunnel Syndrome Pituitary Tumor Growth Hormone Secretion Acromegalic Patient
Unable to display preview. Download preview PDF.
- 2.Lamberts SWJ, Verleun T, Oosterom R. The interrelationship between the effects of somatostatin and human pancreatic growth hormone-releasing factor on growth hormone release by cultured pituitary tumor cells from patients with acromegaly. J Clin Endocrinol Metab 1984; 58: 250–4.PubMedCrossRefGoogle Scholar
- 6.Tolis G, Pitoulis C, Yotis A, et al. Therapy of acromegaly with a mini somatostatin. Program, Endocrine Society, 1984: 488.Google Scholar
- 7.Tolls G. SMS 201–995: long term use in active acromegaly. Neuro-endocrinology Letters 1985; 7: 119.Google Scholar
- 11.Tolls G, Malachtari S, Mortoglou A, et al. Therapy of acromegaly with SMS 201–995: long-term studies. Scand J Gastroenterol 1986 (in press).Google Scholar
- 12.Tolls G, Yotis A, del Pozo E, Pitoulis S. Long-term therapeutic efficacy of a somatostatin analogue (SMS 201–995) in active acromegaly. J Neurosurg 1986 (in press).Google Scholar
- 13.Tolls G, Yotis A, Malachtari S, et al. Follow-up of acromegalic patients treated with an octapeptide somatostatin analogue for over a year. Program, Endocrine Society Annual Meeting, 1986.Google Scholar
- 14.del Pozo E, Kutz K. Pharmacological properties and effects on glucose homeostasis of a somatostatin derivative (SMS 201–995): studies in human. In: Ludecke D, Tolls G, eds. Growth hormone and acromegaly. New York: Raven Press, 1986 (in press).Google Scholar